



TauRx Contributes To ITN Production’s “Hope In The Age Of Dementia”

TauRx Therapeutics Ltd are pleased to announce their work with ITN Productions, ITN’s bespoke production hub, working in partnership with Alzheimer’s Disease International (ADI), goes live on 30th June 2020.

This important program features key industry interviews and news-style reports, along with sponsored editorial profiles. TauRx were invited to contribute to this program to explain their work in the field of neurodegenerative disease and the benefits of taking part in a clinical trial.

Professor Claude Wischik, CEO, says, “It was a pleasure to be part of this news-style program showcasing the latest developments in care, research and technology. The impact of dementia globally has been brought to focus once again by the devastating effects of the Covid-19 pandemic, and now, more than ever, the pharmaceutical industry needs to re-focus its efforts in finding new and effective ways to combat this disease. Our focus at TauRx has always been in the field of neurodegenerative disease and we hope that our contribution to this program will help highlight the progress of research and the importance of patients taking part in clinical trials.”

Here is a link to the programme:

<https://www.youtube.com/playlist?list=PL-y9-0L2Glr3BSExwYvPSRTU5lvne5iVJ>

ADI is the international federation of Alzheimer associations around the world, in official relations with the World Health Organization. Each member is the Alzheimer association in their country who support people with dementia and their families. ADI’s vision is prevention, care and inclusion today, and cure tomorrow.

www.alz.co.uk

ITN Productions produces bespoke creative and commercial content for broadcasters, businesses, brands, rights holders and digital channels. Industry News forms part of this offering and is a communications tool for leading industry bodies and national associations produced in a broadcast news-style programme format, including interviews, news items and sponsored editorial profiles.

TauRx Pharmaceuticals Ltd. 3, Shenton Way, #21-04, Shenton House, Singapore 068805, Republic of Singapore
TauRx Therapeutics Ltd. 3, Shenton Way, #21-04, Shenton House, Singapore 068805, Republic of Singapore
TauRx Research Facility Liberty Building, Foresterhill Road, Aberdeen AB25 2ZP, UK

For further information visit www.taurx.com



www.itnproductions.co.uk

TauRx Therapeutics Ltd is a member of the TauRx Pharmaceuticals group, which is developing technology spun-out from the University of Aberdeen, Scotland. The company was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company's protein aggregation inhibitor, hydromethylthionine, targets aggregates of abnormal fibres of tau and TDP-43 proteins that form inside nerve cells in the brain. TauRx's headquarters are in Singapore and its primary research facilities are based in Aberdeen.

www.taurx.com

Media Contacts

Email: media@taurx.com

Website: <http://www.taurx.com>

TauRx Pharmaceuticals Ltd. 3, Shenton Way, #21-04, Shenton House, Singapore 068805, Republic of Singapore
TauRx Therapeutics Ltd. 3, Shenton Way, #21-04, Shenton House, Singapore 068805, Republic of Singapore
TauRx Research Facility Liberty Building, Foresterhill Road, Aberdeen AB25 2ZP, UK

For further information visit www.taurx.com